Marleen Melis

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Breast cancer imaging using radiolabelled somatostatin analogues.

Breast cancer imaging using radiolabelled somatostatin analogues.

Journal: Nuclear medicine and biology

Published: April 11, 2016

Localization of Radiolabeled Somatostatin Analogs in the Spleen.

Localization of Radiolabeled Somatostatin Analogs in the Spleen.

Journal: Clinical nuclear medicine

Published: October 14, 2015

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.

Journal: EJNMMI research

Published: September 15, 2015

Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.

Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 14, 2015

In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.

In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 15, 2014

In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.

In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.

Journal: Cancer biotherapy & radiopharmaceuticals

Published: October 07, 2014

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount.

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount.

Journal: EJNMMI research

Published: May 26, 2014

Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.

Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.

Journal: EJNMMI research

Published: February 06, 2014

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Journal: Clinical and translational imaging

Published: November 08, 2013

mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.

mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.

Journal: Cancer research

Published: November 15, 2012

Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.

Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 13, 2012

Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.

Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 17, 2010

Showing 1-12 of 16

Last Updated: 09/26/2026